January 2nd 2025
The discussion on NSCLC narrowed in on findings out of recent clinical trials, particularly involving a combination regimen of osimertinib and chemotherapy.
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Patients With ALK+ NSCLC Not Suitable for Crizotinib Benefit from Sequential ALK-Inhibitor Therapy
September 11th 2021Patients with non–small cell lung cancer harboring ALK mutations who were not suitable for crizotinib therapy, either due to resistance or intolerance, showed benefit with sequential crizotinib and alectinib.
Intracranial Activity Seen With Sotorasib for KRAS G12C–Mutated NSCLC Brain Metastases
September 8th 2021For patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases who were previously treated with either radiation or surgery, robust anticancer activity was observed with intracranial complete responses and continued intracranial stabilization with sotorasib.
Pelcitoclax Plus Osimertinib Shows Promise in Patients With EGFR TKI–Resistant NSCLC
September 8th 2021Patients with EGFR-positive non–small cell lung cancer whose disease is not suitable for standard EGFR TKI monotherapy had promising responses and experienced few dose-limiting toxicities with pelcitoclax plus osimertinib.
PFS Benefit Observed With Tislelizumab Plus Chemotherapy for Advanced Squamous NSCLC
September 8th 2021Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.
Higher Risk of Recurrence, Worse Survival Related to Delayed Surgery in Veterans With Stage I NSCLC
August 24th 2021Veterans diagnosed with stage I non–small cell lung cancer who have experienced delays in their surgical treatment over the past 12 weeks are at a higher risk of negative disease outcomes compared with those receiving surgery immediately after diagnosis.
Stephen Liu, MD, on Key Takeaways From the ARROW Trial of Pralsetinib for RET+ NSCLC
July 24th 2021At ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib.
John Heymach, MD, PhD, Discusses the Use of Adjuvant Immunotherapy for Patients With NSCLC
July 23rd 2021CancerNetwork® sat down with John Heymach, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk adjuvant immunotherapy for recurrence-free survival in resected non–small cell lung cancer.
FoundationOne Liquid CDx Approved as Companion Diagnostic for Capmatinib Use in METex14+ NSCLC
July 16th 2021Foundation Medicine announced the expanded indication for FoundationOne Liquid CDx as a companion diagnostic to identify MET exon 14 skipping mutations in metastatic non–small cell lung cancer.